Salt and solid forms of a cdk inhibitor

Crystalline Form I of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 6.8°, 18.4°, 21.4°, and 24.1°±0.2 in 2θ.

Crystalline Form III of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 5.7°, 7.4°, 10.5°, 14.2°, and 20.5°±0.2 in 2θ.

Crystalline Form IV of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 3.8°, 5.4°, and 15.8°±0.2 in 2θ.

Crystalline Form V of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 8.8°, 11.1°, 20.2°, and 23.7°±0.2 in 2θ.

Crystalline Form VI of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 5.6°, 9.9°, 13.7°, and 19.3°±0.2 in 2θ.

Crystalline Form VII of Compound (I):

• characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 5.3°, 5.6°, and 10.2°±0.2 in 2θ.

Crystalline Form I of maleate salt of Compound (I) represented by the following Formula:

• wherein the molar ratio between Compound (I) and maleic acid is 1:1, characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 5.7°, 9.3°, 10.3°, 13.9°, and 20.7°±0.2 in 2θ.

Crystalline Form I of tosylate salt of Compound (I) represented by the following Formula:

• wherein the molar ratio between Compound (I) and p-toluenesulfonic acid is 1:1, characterized by an X-ray powder diffraction pattern which comprises peaks at chosen from 9.5°, 11.0°, 14.1°, 21.4°, and 21.9°±0.2 in 2θ.